CLINICO-EPIDEMIOLOGICAL PROFILE AND QUALITY-OF-LIFE IMPACT OF CHRONIC PLAQUE PSORIASIS: A HOSPITAL-BASED CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.48047/qc9abv77Keywords:
psoriasis, PASI, Dermatology Life Quality Index, comorbidity, psoriatic arthritis, quality of lifeAbstract
Background: Chronic plaque psoriasis is an immune-mediated systemic disease with a substantial quality-of-life burden and recognised metabolic and cardiovascular comorbidities. Hospital-based characterisation informs holistic care.
Objectives: To describe the clinico-epidemiological profile of chronic plaque psoriasis, quantify its impact on quality of life, and examine the relationship between disease severity and quality-of-life impairment.
Methods: A cross-sectional, hospital-based study of 240 patients with chronic plaque psoriasis recorded demographics, disease characteristics, comorbidities, severity (PASI, BSA, PGA) and the Dermatology Life Quality Index (DLQI). Associations used the Pearson correlation and analysis across severity categories. Results: Patients (mean age 44.5 ± 13.4 years; 58.3% male; mean disease duration 9.5 ± 7.0 years) had a mean PASI of 10.3 ± 7.4, mean BSA 18.9 ± 12.8% and mean pruritus VAS 6.0 ± 2.3. Scalp involvement occurred in 64.6%, nail involvement in 29.6% and psoriatic arthritis in 14.6%; a metabolic comorbidity (diabetes, hypertension or dyslipidaemia) was present in a subset. Mean DLQI was 11.4 ± 6.0, indicating a large effect on daily life. DLQI correlated strongly with PASI (r = 0.87, p < 0.001) and BSA (r = 0.81, p < 0.001), and rose across severity categories (mild 6.8, moderate 8.9, severe 16.8).
Conclusion: Chronic plaque psoriasis imposed a substantial and severity-graded quality-of-life burden, with frequent scalp and nail involvement and psoriatic arthritis. The strong PASI–DLQI relationship underscores the value of routinely measuring quality of life and screening for comorbidities alongside clinical severity.
Downloads
References
Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71. doi:10.1186/1477-7525-4-71
Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–534. doi:10.1016/j.clindermatol.2007.08.006
Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260–270. doi:10.1159/000113150
Guenther L, Gulliver W. Psoriasis comorbidities. J Cutan Med Surg. 2009;13 Suppl 2:S77–S87. doi:10.2310/7750.2009.00024
Esposito M, Giunta A, Mazzotta A, Babino G, Talamonti M, Chimenti MS, et al. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience. Int J Immunopathol Pharmacol. 2010;23(2):503–509. doi:10.1177/039463201002300212
Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20(2):81–87. doi:10.1111/j.1600-0625.2010.01210.x
He Z, Lu C, Basra MKA, Ou A, Yan Y, Li L. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(1):109–115. doi:10.1111/j.1468-3083.2011.04371.x
Torres T, Sales R, Vasconcelos C, Selores M. Psoriasis and cardiovascular disease. Acta Med Port. 2013;26(5):601–607.
Spandonaro F, Altomare G, Berardesca E, Calzavara-Pinton P, Chimenti S, Girolomoni G, et al. Health-related quality of life in psoriasis: an analysis of Psocare project patients. G Ital Dermatol Venereol. 2011;146(3):169–177.
Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974–980. doi:10.1111/1346-8138.12653
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
